Rocket Pharmaceuticals is trading 5.5% up at $3.28 after the company provided a positive clinical safety update for RP-A501 in its pivotal Phase 2 Danon disease gene therapy trial.
- The company reported that the first three patients treated under a modified protocol showed good tolerability with no significant safety concerns.
- The update has boosted investor sentiment regarding the company's lead program, with the stock also benefiting from a generally risk-on broader market.